BrainStorm Cell Therapeutics Inc.

Business news, market intelligence, and global industry analysis.

The Latest

Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move

Boliden AB (STO: BOL) warns Garpenberg seismic damage will cut 2026 output and hit Q1 EBITDA

Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?

Representative image of a motorway corridor and capital flows illustrating HICL Infrastructure PLC’s £311 million A63 Motorway stake sale in France, as the London-listed infrastructure investor exits the Atlandes asset at a 21% premium to book value.

HICL Infrastructure (LSE: HICL) to sell A63 Motorway stake for £311m at 21% premium to book value

BrainStorm Cell Therapeutics (OTCQB: BCLI) narrows Q3 2025 loss as ALS trial preps advance and cash runway tightens

BrainStorm Cell Therapeutics narrows Q3 loss and prepares for pivotal ALS trial. Find out why 2026 could be a make-or-break year for the biotech company.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

November 15, 2025